Mylan’s roots are in the U.S., and our products can likely be found in most American homes. In 2017 alone, our generics saved the nation’s healthcare system approximately $20.4 billion. As for manufacturing, a majority of the doses we sell in America are manufactured in America.*

*Manufactured from domestic and imported components.

Access to Medicine

In 2017, Mylan generics saved Vermont

~$38 million

We believe everyone deserves the opportunity to live a healthy life, including you. That’s why our business is focused on providing a sustainable supply of high quality medicine that is accessible, acceptable, available and more affordable to patients around the world.

Innovation & Science

Mylan has global research centers in the U.S. and India and 10 technology-focused sites around the world.

Innovation and science are cornerstones of Mylan's success for nearly 60 years.
They will continue to be the foundation of our future.

Public & Health Policy

One of the most powerful ways to serve patients in need is by speaking out on their behalf.

We work closely with government, trade associations, healthcare providers, patient advocacy groups and others to shape policy to help people in the U.S. enjoy better health.

Community Impact

Mylan person state
Workforce of
400+
people in Vermont
Mylan VT transmendal
Home to Mylan's only transdermal manufacturing site
Mylan comminuty charityupdated

Mylan understands the importance of going beyond our business boundaries to serve the community at large. Through community engagement and philanthropy, we drive access to high quality medicine and build healthy communities, often aligning our community support to our mission and core business through product donations, financial contributions and employee volunteerism.

Mylan's School
Access Program - VT

Over the past five years, Mylan has provided 5,318 free epinephrine auto-injectors to 373 schools in Vermont, ~71% of the state’s schools.

Several years ago, we recognized that epinephrine auto-injectors needed to be as accessible as defibrillators are in public spaces. So Mylan advocated for legislation to permit “undesignated” epinephrine auto-injectors in schools – meaning a prescription could be in a school’s name rather than in a child’s name and any individual experiencing an anaphylactic emergency would have access to the epinephrine auto-injectors. Today, 48 states have adopted such laws, and Mylan has donated nearly 1 million epinephrine auto-injectors to more than 73,000 schools around the country through the school access program.

Since the program began, epinephrine auto-injectors provided through the program have been used at least 11 times in Vermont in the school setting.